A European network of paediatric research at the European Medicines Agency (Enpr-EMA)

Archives of Disease in Childhood

Volumn 97, Issue 3, 2012, Pages 185-188

  Ruperto, Nicolino ^a   Eichler, Irmgard ^b   Herold, Ralf ^b   Vassal, Gilles ^c   Giaquinto, Carlo ^d   Hjorth, Lars ^e   Valls i Soler, Adolf ^f   Peters, Christina ^g   Helms, Peter J ^h   Raymond, Agnès Saint ^b  

^a G GASLINI INSTITUTE   (Italy)

^b EUROPEAN MEDICINES AGENCY   (United Kingdom)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Intl Maternal Pediatric Adolescent AIDS Clinical Trials   (Italy)

^e LUND UNIVERSITY   (Sweden)

^f UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^g ST ANNA CHILDREN S HOSPITAL   (Austria)

^h UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SURVIVAL; CHILD; CHILD HEALTH CARE; CHILDHOOD CANCER; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); FOOD AND DRUG ADMINISTRATION; HUMAN; LAW; MEDICAL RESEARCH; MEDICAL SOCIETY; METHODOLOGY; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE;

BIOMEDICAL RESEARCH; CHILD; CLINICAL TRIALS AS TOPIC; DRUG THERAPY; EUROPE; HUMANS; INTERNATIONAL COOPERATION; PEDIATRICS;

EID: 84857227050     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2011-300286     Document Type: Review

References (40)

1. Ruperto N, Martini A. Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO). Arch Dis Child 2011;96:596-601.
2. Regulation (EC) no 1901/2006 of the European parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union 2006;L 378:1-19.
3. The Network of Paediatric Networks at the EMEA Implementing Strategy (Doc. Ref. EMEA/ MB/543523/2007). available at http://www. ema.europa.eu/docs/ en-GB/document-library/ Regulatory-and-procedural-guideline/2009/12/WC500026679. pdf (accessed 18 November 2011).
4. List of paediatric networks at the European Medicine Agency (EMA). available at http://www.ema.europa. eu/docs/en-GB/document-library/Other/2009/ 11/ WC500007143.pdf (accessed 18 November 2011).
5. Mann G, Attarbaschi A, Schrappe M, et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood 2010;116:2644-50.
6. Ladenstein R, Valteau-Couanet D, Brock P, et al. Randomized Trial of prophylactic granulocyte colonystimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol 2010;28:3516-24.
7. Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 2009;361:1662-70.
8. Geoerger B, Doz F, Gentet JC, et al. Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies. J Clin Oncol 2008;26:4394-400.
9. O'Leary M, Krailo M, Anderson JR, et al. Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group. Semin Oncol 2008;35:484-93.
10. Gatta G, Zigon G, Capocaccia R, et al. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 2009;45:992-1005.
11. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9. (Pubitemid 30151920)
12. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infl iximab plus methotrexate for the treatment of polyarticularcourse juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106. (Pubitemid 47502757)
13. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
14. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91.
15. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. doubleblind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992;326:1043-9.
16. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201. (Pubitemid 38924397)
17. Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010;303:1266-73.
18. Ruperto N, Giannini EH, Pistorio A, et al. Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs. Arthritis Rheum 2010;62:3131-9.
19. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary defi nition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9. (Pubitemid 27430130)
20. Ruperto N, Ravelli A, Cuttica R, et al. The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Arthritis Rheum 2005;52:2854-64. (Pubitemid 41369116)
21. Ruperto N, Ravelli A, Oliveira S, et al. The Pediatric Rheumatology International Trials Organization/ American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the defi nition of improvement. Arthritis Rheum 2006;55:355-63. (Pubitemid 43887020)
22. Ruperto N, Ravelli A, Pistorio A, et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008;59:4-13. (Pubitemid 351171873)
23. Ruperto N, Pistorio A, Ravelli A, et al. The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010;62:1533-41.
24. Ruperto N, Garcia-Munitis P, Villa L, et al. PRINTO/ PRES international website for families of children with rheumatic diseases: www.pediatric- rheumatology. printo.it. Ann Rheum Dis 2005;64:1101-6. (Pubitemid 40909540)
25. Ruperto N, Nikishina I, Pachanov ED, et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and longterm effi cacy and safety results. Arthritis Rheum 2005;52:563-72. (Pubitemid 40216321)
26. Mok JQ, Giaquinto C, De Rossi A, et al. Infants born to mothers seropositive for human immunodeficiency virus. Preliminary fi ndings from a multicentre European study. Lancet 1987;1:1164-8.
27. Gibb DM, Darbyshire JH, Debré M, et al. Treatment of children with HIV infection. PENTA (Paediatric European Network for Treatment of AIDS). Lancet 1995;345:1115.
28. Gibb DM, Giaquinto C. Children with HIV infection: special cases. Lancet 2000;356 Suppl:s34. (Pubitemid 32052086)
29. Green H, Gibb DM, Walker AS, et al. Lamivudine/ abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/ abacavir beyond 5 years in children. AIDS 2007;21:947-55. (Pubitemid 46684326)
30. Welch S, Sharland M, Lyall EG, et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009;10:591-613.
31. Babiker A, Castro nee Green H, Compagnucci A, et al. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an openlabel, randomised phase 2/3 trial. Lancet Infect Dis 2011;11:273-83.
32. Valls-i-Soler A, Madrid M, Geffers C, et al. Preventing sepsis in VLBW infants: experience from neonatal networks and voluntary surveillance systems. NeoReviews 2011;11:403-8.
33. The Vermont Oxford Trials Network. A multicenter randomized trial comparing natural surfactant extract to synthetic surfactant in the treatment of RDS. Society for Pediatric Research, Seattle, Washington, May 1994. (Poster Session). Pediatr Res 1994;35:295A.
34. Valls-i-Soler A, Carnielli V, Claris O, et al. EuroNeoStat: a European information system on the outcomes of care for very-low-birth-weight infants. Neonatology 2008;93:7-9.
35. Report on First Workshop on a European Paediatric Research network, 16 February 2009. EMEA. available at http://www.ema.europa.eu/docs/en-GB/document- library/Report/2009/11/WC500007142. pdf (accessed 18 November 2011).
36. Ruperto N, Meiorin S, Iusan SM, et al. Consensus procedures and their role in pediatric rheumatology. Curr Rheumatol Rep 2008;10:142-6.
37. Delbecq AL, Van de Ven AH, Gustafson DH. Group Techniques for Program Planning. A Guide to Nominal Group and Delphi Processes. 1. Glenview, Ill, Scott: Foresman and Company 1975.
38. Report on Second Workshop of the European Paediatric Research Network (EnprEMA), 16 March 2010. available at http://www.ema.europa.eu/docs/en-GB/ document-library/Report/2010/05/ WC500090616.pdf (accessed 18 November 2011).
39. European Medicines Agency (EMA). Enpr- EMA membership. available at http://www. ema.europa.eu/ema/index.jsp?curl=pages/ partners-and-networks/q-and- a/q- and-a-detail-000108.jsp&murl=menus/ partners-and-networks/partners-and- networks. jsp&mid=WC0b01ac05802b9f0f.
40. European Network of Paediatric Research (EnprEMA). Recognition criteria for self assessment. 2010, May 5 Available at http://www.ema.europa.eu/docs/en- GB/document-library/Other/2011/01/WC500100441.pdf (accessed 18 November 2011).